Dual antiplatelet therapy in patients with minor stroke or high-risk transient ischemic attack carrying CYP2C19 loss-of-function alleles
10.3760/cma.j.issn.1673-4165.2023.08.007
- VernacularTitle:携带 CYP2C19功能缺失等位基因的轻型卒中或高危短暂性脑缺血发作患者的双重抗血小板治疗
- Author:
Jinpeng OU
1
;
Yi LIU
;
Jie MA
Author Information
1. 山西医科大学第五临床医学院，太原 030000
- Keywords:
Stroke;
Ischemic attack, transient;
Cytochrome P-450 CYP2C19;
Polymorphism, genetic;
Alleles;
Platelet aggregation inhibitors;
Clopidogrel
- From:
International Journal of Cerebrovascular Diseases
2023;31(8):600-605
- CountryChina
- Language:Chinese
-
Abstract:
Dual antiplatelet therapy has been widely used for the secondary prevention in patients with minor stroke and high-risk transient ischemic attack (TIA). Currently, the commonly used antiplatelet drugs are aspirin and clopidogrel. The therapeutic effect of antiplatelet drugs varies among individuals, namely platelet resistance. Among them, aspirin resistance is often caused by poor drug compliance, while clopidogrel resistance is often associated with CYP2C19 allele mutations. Patients with minor stroke and high-risk TIA carrying CYP2C19 loss-of-function alleles have poor preventive effects when using clopidogrel. Early screening of the CYP2C19 loss-of-function alleles and targeted measures can benefit such patients. This article reviews the research progress on the selection of antiplatelet therapy for minor stroke or high-risk TIA patients carrying the CYP2C19 loss-of-function alleles.
